PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Articles

Search & filter insights:

Search & filter insights:

Use of AI in the patent industry: The spectre of hallucination

  • 10th October 2025
What are the risks of AI hallucinations for the patent industry?

Use of AI in the patent industry: Solving the confidentiality problem

  • 10th October 2025
How can patent attorneys ensure client confidentiality when using AI software for patents.

Evolve Intellectual Property celebrates 4 years!

  • 8th October 2025
Last month, Evolve celebrated its 4-year anniversary in style with a sparkling wine and canapés reception in Cambridge. Thank you to everyone who attended and for our clients’ continued trust and support. We look forward to many more years of helping our clients in their mission to deliver innovative medicines to market and bring hope…

Evolve AI: Building AI tools for IP that are expert-led and pharma-specific

  • 2nd October 2025
We believe that the value of AI for our profession lies in developing highly specialised tools that build upon and incorporate domain-specific attorney expertise.

The unforgiving gold standard: Why deleting a feature can add matter at the EPO (T 0422/23)

  • 30th September 2025
Addition by subtraction: How deleting a feature from a patent claim can fall foul of the EPO’s unforgiving rules on added matter.

The party’s over: EBA leaves late interveners stranded (G2/24)

  • 26th September 2025
Can a third party intervener take over a withdrawn appeal at the EPO? The EBA gives a clear ‘No’.

Overcoming the freedom to operate and patentability challenges for cell therapies

  • 9th September 2025
How do you navigate the freedom to operate and patentability challenges in a field as complex, competitive and crowded as cell therapy?

Bridging the innovation and commercialisation gap: IP strategy for advanced therapies

  • 5th September 2025
Three principles of effective IP strategy for cell and gene therapies.

IP strategy for the universal cell therapy revolution

  • 27th August 2025
The cell therapy landscape is at a pivotal moment. There is a considerable pressure within the industry to solve the manufacturing and logistical challenges that have defined the first generation of cell therapies.

Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023)

  • 12th August 2025
A new ruling in Agfa v Gucci reveals a split between the UPC and the EPO on claim interpretation, with the UPC using a patent’s own ‘lexicon’ to narrow a claim, a decision with major implications for patent holders in Europe.

The great consolidation: Big pharma buys the advanced therapy technology, not just the drug

  • 8th August 2025
The latest cell and gene therapy industry trends reveals a shift in strategy towards platforms.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.
Previous Next

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us